PathMaker Neurosystems Announces Initiation of First-in-Human Trial in ALS for Non-Invasive Neuromodulation Device
14 sept. 2023 06h00 HE
|
PathMaker Neurosystems Inc.
BOSTON and PARIS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the...
Global Amyotrophic Lateral Sclerosis Market Size to Reach USD 1,034.7 Million in 2032 | Emergen Research
29 août 2023 08h56 HE
|
Emergen Research
Vancouver, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The worldwide market for amyotrophic lateral sclerosis achieved a size of USD 613.0 million in the year 2022. According to the most recent study...
Amyotrophic Lateral Sclerosis Treatment Market to Surpass 138.58 Million by 2030 Drives Due to the Availability of Improved Healthcare Expenditure
27 juil. 2023 09h15 HE
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford USA, July 27, 2023 (GLOBE NEWSWIRE) -- According to SkyQuest, the rise in the prevalence of amyotrophic lateral sclerosis treatment market has driven a surge in demand for effective...
Amyotrophic Lateral Sclerosis Market to Surge Immensely by 2032, Predicts DelveInsight | Key Companies to Watch Out - Cytokinetics, Orphazyme, Orion, Biogen, AB Science, Ionis, Biohaven, MediciNova, NeuroSense
19 juil. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, July 19, 2023 (GLOBE NEWSWIRE) -- Amyotrophic Lateral Sclerosis Market to Surge Immensely by 2032, Predicts DelveInsight | Key Companies to Watch Out - Cytokinetics, Orphazyme, Orion,...
Amyotrophic Lateral Sclerosis Treatment Market to Reach US$ 594.1 Million in 2031, Expanding at a CAGR of 5.5%: TMR Report
26 juin 2023 13h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, June 26, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. – In 2022, the global industry was estimated to be worth $594.1 million. It is expected to...
PathMaker Neurosystems Receives $200,000 START Award from MassVentures
05 juin 2023 06h00 HE
|
PathMaker Neurosystems Inc.
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of...
AB Science résume les messages clés de sa participation à une table ronde lors du ALS Drug Development Summit 2023
17 mai 2023 14h15 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE RÉSUME LES MESSAGES CLÉS DE SA PARTICIPATION À UNE TABLE RONDE LORS DU ALS DRUG DEVELOPMENT SUMMIT 2023 (BOSTON, ETATS-UNIS) Paris, 17 mai 2023, 20h00 AB Science SA...
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit
17 mai 2023 14h15 HE
|
AB Science
PRESS RELEASE AB SCIENCE SUMMARIZES KEY MESSAGES FROM ITS PARTICIPATION TO A PANEL DISCUSSION AT THE 2023 ALS DRUG DEVELOPMENT SUMMIT (BOSTON, USA) Paris, 17 May, 2023, 8:00pm CET AB Science SA...
AB Science annonce que Health Canada a repris la revue du dossier d’enregistrement du masitinib dans la sclérose latérale amyotrophique, suite à l’examen préliminaire de la réponse soumise par AB Science
09 mai 2023 12h06 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE QUE HEALTH CANADA A REPRIS LA REVUE DU DOSSIER D’ENREGISTREMENT DU MASITINIB DANS LA SCLEROSE LATERALE AMYOTROPHIQUE, SUITE A L’EXAMEN PRELIMINAIRE DE LA...
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter
09 mai 2023 12h06 HE
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS RESUMED ITS REVIEW OF THE NEW DRUG SUBMISSION FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS, FOLLOWING ISSUANCE OF A SCREENING ACCEPTANCE...